MOR

MorphoSys AG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.47
-1.76
-5.14%
Opening 11:03 09/21 EDT
OPEN
32.86
PREV CLOSE
34.23
HIGH
32.87
LOW
32.27
VOLUME
16.01K
TURNOVER
--
52 WEEK HIGH
37.96
52 WEEK LOW
18.21
MARKET CAP
4.25B
P/E (TTM)
36.36
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 3d ago
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
Phase 1 Clinical Study Expected to Start in Q4 2020 PLANEGG & MUNICH GERMANY AND SHANGHAI, CHINA / ACCESSWIRE / September 17, 2020 / MorphoSys AG (FSE:MOR)(Prime Standard Segment, MDAX & TecDAX; (NASDAQ:MOR) and I-Mab (NASDAQ:IMAB) today jointly announced that the U.
ACCESSWIRE · 3d ago
FDA gives go ahead signal for early-stage study for MorphoSys/I-Mab' monoclonal antibody in solid tumors
MorphoSys's (MOR) and its collaborating partner, I-Mab (IMAB) announce that the FDA has signed off Phase 1 trial for MOR210/TJ210 for the treatment of relapsed or refractory advanced solid tumors.MOR210/TJ210 is a monoclonal antibody that
Seekingalpha · 3d ago
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Business Wire · 3d ago
National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Business Wire · 08/18 21:02
MorphoSys' tafasitamab added to U.S. treatment guidelines for type of blood cancer
MorphoSys AG (MOR) and collaborator/licensee Incyte (INCY) announce that Monjuvi (tafasitamab-cxix) has been added to the National Comprehensive Cancer Network ((NCCN)) Clinical Practice Guidelines in Oncology for B-cell lymphomas.Specifically, the NCCN
Seekingalpha · 08/18 20:17
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 08:46
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 08/03 16:12
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MOR stock price target is 43.18 with a high estimate of 43.18 and a low estimate of 43.18.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 4.45M
% Owned: 3.40%
Shares Outstanding: 130.87M
TypeInstitutionsShares
Increased
15
513.02K
New
14
-311.39K
Decreased
10
3.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.13%
Pharmaceuticals & Medical Research
-2.72%
Key Executives
Chairman - Supervisory/Independent Director
Marc Cluzel
Chief Executive Officer
Jean-Paul Kress
Chief Financial Officer/Management Board
Jens Holstein
Corporate Executive
David Trexler
Vice President/Director of Investor Relations
Sarah Fakih
Management Board
Malte Peters
Management Board
Roland Wandeler
Independent Director/Supervisory Board
Sharon Curran
Independent Director/Supervisory Board
Wendy Johnson
Supervisory Board
Michael Brosnan
Supervisory Board
George Golumbeski
Supervisory Board
Krisja Vermeylen
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average MOR stock price target is 43.18 with a high estimate of 43.18 and a low estimate of 43.18.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MOR
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Morphosys Ag (ADR) stock information, including NASDAQ:MOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MOR stock methods without spending real money on the virtual paper trading platform.